AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00076752
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Priming regimen:1000 mg intravenous over 30 minutes, day 1.
Trial: NCT00076752
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conditioning and transplant regimen 25-50 mg orally or intravenously.
Trial: NCT00076752
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Priming regimen: 600 mg/m\^2 intravenous immediately prior to cyclophosphamide and repeat at 4 and 7 hours after the first dose, day 2. Conditioning and transplant regimen:1200 mg/m\^2 per day continuous 24 hour intravenous infusion, daily for 4 days, start concurrently with the start of cyclophosphamide.
Trial: NCT00314561
Drug: Pioglitazone, Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00637130
Drug: Travoprost ophthalmic solution, 0.0008%
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00637130
Drug: Travoprost ophthalmic solution, 0.001%
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00637130
Drug: Travoprost ophthalmic solution, 0.0012%
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00637130
Drug: TRAVATAN
RxNorm normalized name: Travatan
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02032186
Drug: Magnesium citrate
RxNorm normalized name: Magnesium Citrate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Mg++citrate, 160 mg twice daily. Each capsule will contained 160 mg of elemental magnesium citrate. The participants will be instructed to take one capsule twice daily until delivery.
Trial: NCT00563810
Drug: MYO-029
RxNorm normalized name: MYO-029
DrugBank: Stamulumab (DB05915)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00394836
Drug: Ofatumumab
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Eight weekly infusions of ofatumumab. The first infusion of 300mg ofatumunab
Trial: NCT00394836
Drug: Ofatumumab
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: followed by 7 weekly infusions of 1000mg ofatumumab
Trial: NCT00100113
Drug: GBR 12909
RxNorm normalized name: GBR-12783
DrugBank: GBR-12783 (DB17027)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00304512
Drug: migalastat HCl
RxNorm normalized name: migalastat HCl
DrugBank: Migalastat (DB05018)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02054351
Drug: IMAB027
RxNorm normalized name: IMAB027
DrugBank: IMAB027 (DB17282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage 1 (Intrapatient dose escalation): The starting dose is set to 1 mg/m2, followed by 10 mg/m2, 30 mg/m2 and 100 mg/m2 Stage 2 (Interpatient dose escalation): 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2 Extension period: 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2
Trial: NCT04108104
Drug: Cyproheptadine
RxNorm normalized name: Cyproheptadine
DrugBank: Cyproheptadine (DB00434)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-month treatment
Trial: NCT00506896
Drug: intraarticular injection
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Triamcinolone hexacetonide 60mg(3ml)by intraarticular injection Triamcinolone acetonide 60mg (3ml)by intramuscular administration
Trial: NCT02817516
Drug: TAK-828
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-828 solution.
Trial: NCT00664859
Drug: LCP-AtorFen
RxNorm normalized name: LCP-AtorFen
DrugBank: LCP-AtorFen (DB05769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will be assigned to receive open-label LCP-AtorFen combination therapy for 52 weeks. Subjects will take a single oral dose of study drug in the evening without regard to meals.
Trial: NCT03117595
Drug: Bupivacaine-fentanyl
RxNorm normalized name: Bupivacaine-Fentanyl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosages as previously written
Trial: NCT03117595
Drug: Bupivacaine-fentanyl morphine
RxNorm normalized name: Fentanyl
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosage as previously written
Trial: NCT01403025
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Once daily at a fixed timing, and subcutaneously (under the skin) in the abdomen, in the thigh or in the upper arm
Trial: NCT02557932
Drug: Bismuth quadruple therapy
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30mg, 2 times a day + Bismuth 300mg, 4 times a day + Tetracycline 500mg, 4 times a day + Metronidazole 500mg, 3 times a day for 10 days
Trial: NCT03375671
Drug: Ketalar
RxNorm normalized name: Ketalar
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single administration of 5 mg/kg, IM
Trial: NCT03472456
Drug: Implementation of a pulp medication in compliance with the dental emergency management protocol: eugenol
DrugBank: Eugenol (DB09086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implementation of a pulp medication in compliance with the dental emergency management protocol: eugenol
Trial: NCT02676401
Drug: MT-3995 Low
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02676401
Drug: MT-3995 Middle
RxNorm normalized name: WHEAT MIDDLINGS
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02676401
Drug: MT-3995 High
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004902
Drug: tocladesine
RxNorm normalized name: Tocladesine
DrugBank: Tocladesine (DB13046)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02426723
Drug: Phase 1b: CWP232291, Lenalidomide, Dexamethasone
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: CWP232291 administered twice weekly every 4 weeks. Lenalidomide and Dexamethasone administered per standard therapy.
Trial: NCT04026165
Drug: SEL
RxNorm normalized name: Selen
DrugBank: Selenium (DB11135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once daily
Trial: NCT03375671
Drug: Midazolam injection
RxNorm normalized name: midazolam Injection
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: single administration of 5 mg, IM
Trial: NCT03375671
Drug: Haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single administration of 5 mg, IM
Trial: NCT02637895
Drug: Vortioxetine
RxNorm normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Immediate Release 10 mg. Vortioxetine Pill
Trial: NCT00369070
Drug: AMG 706
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects in Arms A and B will take AMG 706 orally in one of two dosing regimens over each 21-day cycle: •Arm A: 125 mg once daily (QD) •Arm B: 75 mg twice daily every 12 ± approximately 1 hour for 5 days followed by a 2 day treatment free period every 7 days
Trial: NCT00369070
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All subjects will receive a paclitaxel chemotherapy regimen (paclitaxel 200 mg/m2) on day 1 of each 3-week cycle for a maximum of 6 cycles.
Trial: NCT00369070
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All subjects will receive carboplatin chemotherapy regimen (carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3-week cycle for a maximum of 6 cycles.
Trial: NCT03471169
Drug: Desirable TEG
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Change the type and dose of antithrombotic therapy and obtain desirable TEG results.~Antithrombotic drugs inclued Bayaspirin®，Plavix ® and Cilostazol.
Trial: NCT02989649
Drug: Alogliptin
RxNorm normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alogliptin tablets
Trial: NCT02989649
Drug: Alogliptin FDC With Pioglitazone
RxNorm normalized name: alogliptin / pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alogliptin FDC with pioglitazone tablets
Trial: NCT02989649
Drug: Alogliptin FDC With Metformin
RxNorm normalized name: alogliptin / metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Alogliptin FDC with metformin tablets
Trial: NCT01363752
Drug: Advagraf
RxNorm normalized name: Astagraf
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01363752
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral
Trial: NCT01363752
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral
Trial: NCT02111785
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment with a short course of oral dexamethasone
Trial: NCT00972556
Drug: Gray Mineral Trioxide Aggregate (GMTA)
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once hemorrhage from the pulp chamber is under control using direct pressure of a sterile cotton pellet, pulp stumps are covered with a MTA paste, obtained by mixing 0.2g GMTA powder with sterile water in a powder to liquid ratio of 3:1 in weight. The GMTA will be then immediately covered with a zinc-oxide eugenol base (IRM) material.
Trial: NCT00972556
Drug: Diluted (20%) Formocresol (DFC)
RxNorm normalized name: phenol
DrugBank: Cresol (DB11143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After the pulp hemostasis is achieved with direct pressure of a sterile cotton pellet, a sterile cotton pellet dampened with 20% DFC will be placed in contact with the pulp for 5 minutes, followed by the immediate placement of a zinc-oxide eugenol base (IRM) material.
Trial: NCT03790228
Drug: Anlotinib Combined With Pemetrexed And Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anlotinib(12mg, QD, PO, d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2, IV, d15-21,21 days per cycle) and Carboplatin(AUC5,IV, d15-21,21 days per cycle,using 4 cycles)
Trial: NCT03562611
Drug: Nalbuphine
RxNorm normalized name: Nalbuphine
DrugBank: Nalbuphine (DB00844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nalbuphine administration during surgery
Trial: NCT03562611
Drug: Flurbiprofen Axetil
RxNorm normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen axetil administration during surgery
Trial: NCT00631410
Drug: sunitinib + mFOLFOX6
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 37.5 mg/day, oral, administered on an outpatient basis for 4 weeks on, 2 weeks off (Schedule 4/2)
Trial: NCT00682370
Drug: saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous infusion, single dose
Trial: NCT00682370
Drug: heme arginate
RxNorm normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion, single dose~0.3 mg/kg heme arginate
Trial: NCT00682370
Drug: heme arginate
RxNorm normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion, single dose~1 mg/kg heme arginate
Trial: NCT00682370
Drug: heme arginate
RxNorm normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion, single dose~3 mg/kg heme arginate
Trial: NCT02500147
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin ER 500 mg once a day for one week and 1000 mg once a day for the remainder of the six months
Trial: NCT04433091
Drug: 2-Hydroxybenzylamine
RxNorm normalized name: hydroxybenzopyridine
DrugBank: Benzylamine (DB02464)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-HOBA (2-Hydroxybenzlamine) 750mg will be given TID seven days prior to ablation and 28 days post ablation.
Trial: NCT04448561
Drug: morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02976779
Drug: OWC MGC cream
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cream containing 3% CBD and 3% THC for Psoriasis treatment
Trial: NCT00782184
Drug: atorvastatin 40 mg
RxNorm normalized name: atorvastatin 40 MG
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atorvastatin 40 mg tablet once daily for 6 weeks
Trial: NCT00782184
Drug: atorvastatin 20 mg
RxNorm normalized name: atorvastatin 20 MG
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will take atorvastatin 20 mg tablet once daily for the 5 week run-in period before randomization
Trial: NCT03830684
Drug: Baicalein Tablets 400mg
RxNorm normalized name: Baicalein
DrugBank: Baicalein (DB16101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 Baicalein Tablets and 2 placebo per time, three times a day
Trial: NCT03830684
Drug: Baicalein Tablets 600mg
RxNorm normalized name: Baicalein
DrugBank: Baicalein (DB16101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 Baicalein Tablets per time, three times a day
Trial: NCT02327403
Drug: Belatacept
RxNorm normalized name: Belatacept
DrugBank: Belatacept (DB06681)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Conversion from calcineurin-inhibitor to Belatacept maintenance immunosuppression.
Trial: NCT02738879
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin 100 mg, oral, once daily for 30 weeks
Trial: NCT02738879
Drug: Placebo to sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks
Trial: NCT02738879
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: At least 1500 mg/day, oral, twice daily for participants entering the study on immediate-release metformin + sitagliptin or a fixed dose combination (FDC).
Trial: NCT04387630
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral hypoglycemic drug. Initial dose 500-850 mg/d. incrementally increased to a maximum daily dose of 2550 mg in three divided doses.
Trial: NCT02738879
Drug: Metformin XR
RxNorm normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: At least 1500 mg/day, oral, once daily for participants entering the study on extended-release metformin + sitagliptin or a FDC.
Trial: NCT02738879
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (LANTUS®) initiated at 10 units and titrated based on a treat-to-target algorithm to achieve fasting glucose levels of 72-100 mg/dL (4-5.6 mmol/L); administered once daily subcutaneously.
Trial: NCT02233101
Drug: Oral Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive 1950mg of oral prior to surgery to help reduce blood loss during total joint replacement
Trial: NCT02233101
Drug: Intravenous Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 1950mg of intravenous Tranexamic Acid prior to total joint arthroplasty and blood loss or need for transfusion within 24 hours post operative
Trial: NCT01302444
Drug: Tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tadalafil 40mg for 12 weeks
Trial: NCT04241744
Drug: Vancomycin 125 MG po BID
RxNorm normalized name: vancomycin 125 MG
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: prevention to develop CDI during hospitalization
Trial: NCT00447031
Drug: intravitreal bevacizumab and triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02360631
Drug: Chantix
RxNorm normalized name: Chantix
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A drug used to treat nicotine addiction.Chantix is approved by the FDA to be given to help people quit smoking.
Trial: NCT02689869
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib (PCI-32765; JNJ-54179060) is a first-in-class, potent, orally-administered covalently-binding small molecule inhibitor of Bruton's tyrosine kinase currently being co-developed by Janssen Research \& Development, LLC and Pharmacyclics, Inc for the treatment of B-cell malignancies.
Trial: NCT03627039
Drug: SGLT2
RxNorm normalized name: Sodium-glucose co-transporter 2 (SGLT2) inhibitors
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All SGLT2 medications approved prior to 2017 will be included (Canagliflozin, empagliflozin, dapagliflozin (all doses, all of the medications are oral)
Trial: NCT03627039
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin is the main comparator of interest. In a secondary analysis GLP1 will be the comparator
Trial: NCT01760421
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (200mg/tab) 1 tab twice daily orally for 6 months
Trial: NCT02050919
Drug: Epirubicin Hydrochloride
RxNorm normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02050919
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02050919
Drug: Sorafenib Tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02784613
Drug: Ospemifene
RxNorm normalized name: Ospemifene
DrugBank: Ospemifene (DB04938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: FDA approved medication for the treatment of vulvovaginal atrophy and dyspareunia
Trial: NCT02103959
Drug: CMX-2043
RxNorm normalized name: CMX-2043
DrugBank: CMX-2043 (DB12795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow bolus IV administration of CMX-2043
Trial: NCT02822573
Drug: Donepezil 5 mg
RxNorm normalized name: donepezil 5 mg oral tablet
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be asked to take one 5 mg tablet of donepezil daily for 6 weeks followed by two 5mg tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
Trial: NCT03891862
Drug: Valbenazine
RxNorm normalized name: Valbenazine
DrugBank: Valbenazine (DB11915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vesicular monoamine transporter 2 (VMAT2) inhibitor
Trial: NCT00003134
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05081700
Drug: All patients in the study will be treated with ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300 mg of OCR IV infusion will be given on Day 0 followed by a second dose of 300 mg OCR 14 days later ± 2 days, and then 600 mg of OCR as a single infusion will be given every 24 weeks thereafter per standard medical care.
Trial: NCT02855359
Drug: denintuzumab mafodotin
RxNorm normalized name: Denintuzumab mafodotin
DrugBank: Depatuxizumab mafodotin (DB11731)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGN-CD19A at 3 mg/kg will be administered every 6 weeks via intravenous (IV) infusion, up to a maximum of three (3) doses, on Day 1 of Cycles 1, 3, and 5 of 21-day cycles
Trial: NCT02855359
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
Trial: NCT02855359
Drug: vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)
Trial: NCT02855359
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles
Trial: NCT00262470
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg PO x 1
Trial: NCT00262470
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-40 mg PO x 1 dose